Fulcrum Therapeutics
FULC
88 hedge funds and large institutions have $183M invested in Fulcrum Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 31 reducing their positions, and 43 closing their positions.
723% more call options, than puts
Call options by funds: $2.16M | Put options by funds: $262K
6% more capital invested
Capital invested by funds: $172M → $183M (+$11M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.93% less ownership
Funds ownership: 97.82% → 89.89% (-7.9%)
16% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 31
24% less funds holding
Funds holding: 116 → 88 (-28)
65% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.81M |
| 2 |
CAC
Cowen and Company
New York
|
+$2.76M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1.75M |
| 4 |
RI
RTW Investments
New York
|
+$1.62M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.84M |
| 2 |
VA
VR Adviser
New York
|
-$3.73M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.08M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.23M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.19M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
126
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$8.12K | -2,849 | Closed |
|
127
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$3.95K | -1,385 | Closed |
|
128
Russell Investments Group
London,
United Kingdom
| – | -$2.64K | -925 | Closed |
|
|
LC
129
Lindbrook Capital
Calabasas,
California
| – | -$333 | -117 | Closed |
|
130
Osaic Holdings
Scottsdale,
Arizona
| – | -$26 | -9 | Closed |
|
FULC Hedge Fund Activity: Q2 2023 in Review
88 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q2 2023, worth a combined $183M — up 6.4% from $172M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of FULC and 15 opened new positions — a net loss of 28 holders — while 31 trimmed existing stakes and 26 added.
The largest buyer was Citadel Advisors, adding an estimated $3.81M. The largest seller was BlackRock, cutting an estimated $7.84M.
- 88 institutional investors held Fulcrum Therapeutics (FULC) as of Q2 2023, down from 116 in Q1 2023.
- Funds reported $183M of Fulcrum Therapeutics stock for Q2 2023, up 6.4% quarter-over-quarter.
- 15 funds opened new Fulcrum Therapeutics positions in Q2 2023 and 43 closed out, a net change of -28 holders.
- The largest Fulcrum Therapeutics buyer in Q2 2023 was Citadel Advisors, an estimated $3.81M added.
- The largest Fulcrum Therapeutics seller in Q2 2023 was BlackRock, an estimated $7.84M sold.
Based on aggregated 13F filings for Q2 2023.